![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Anglo Asian Mining Plc | LSE:AAZ | London | Ordinary Share | GB00B0C18177 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.50 | 0.56% | 90.50 | 87.00 | 94.00 | 90.50 | 90.50 | 90.50 | 38,407 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Miscellaneous Metal Ores,nec | 45.86M | -24.24M | -0.2122 | -4.26 | 102.82M |
Date | Subject | Author | Discuss |
---|---|---|---|
18/10/2020 15:04 | Not quite the breakthrough in diplomacy and common sense that I was hoping for over this weekend unfortunately, but it could again present further buying opportunities around 100p...? We are but passengers, you buy a ticket or walk, each to their own.. :o) | laurence llewelyn binliner | |
18/10/2020 14:43 | wan Ta :) | ![]() winston66 | |
18/10/2020 14:34 | yes it is w66 :-) Cheers Wan :-) | wanobi | |
18/10/2020 13:47 | The Stigologist I'm not a scientist but my reading of the slide you have posted is that on the mice tested for Breast carcinoma, the ICI's recorded 0% tumour volume at 28 days, against 55.29% vs untreated and 51.97% vs vehicle comparisons for MRx0518 in monotherapy. For Kidney carcinoma the ICI's were still at 0% tumour volume at 22days and MRx0518 was at 40.06% and 80.49% vs the untreated and vehicle measures respectively. In Lung carcinoma the ICI's were at 145.17% and 133.14% with Mrx0518 at 81.02% and 75.05% after 24 days, again vs the untreated and vehicle measurements. So am I right in saying that MRx0518 shows promise in lung carcinoma against current treatments but not so good in the other two sub-types when compared to ICI's ? And I suppose the relatively poor showing of the ICI's in Lung carcinoma backs up the fact that this is a particularly difficult patient group to treat. edit: ICI's- Immune Checkpoint Inhibitors such as Yervoy, Keytruda and Opdivo. | ![]() winston66 | |
18/10/2020 13:31 | Think I will go with AVCT this week for the comp - may not be their test being trialed at the moment, but can't be too far away from clinical validation now and should hopefully see continued interest with mass testing on the agenda? | ![]() king suarez | |
18/10/2020 13:05 | I was banging on about 4D on this thread at 20p and 40p and 60p and 80p and i'm sure as hell going to bang on about it at 100p I EXPECT a 10 bagger There is a chance of a 100 bagger read my latest post on 4D thread for why that is possible | ![]() the stigologist | |
18/10/2020 12:50 | wanobi Is that a gap at the top of the 4D chart aswell ? Just above the long blue candle. | ![]() winston66 | |
18/10/2020 12:26 | I'm now thinking AZER will push on, defeat ARM and take back NK,,,, just a question of how long it will take before ARM give up and leave the region... but, who knows pogue,,, we'll just have to wait and see what unfolds,,,,, cheers Wan... | wanobi | |
18/10/2020 12:23 | thanx Brasso, yep :-) Cheers Wan :-) | wanobi | |
18/10/2020 12:13 | Wan 4D - We had the same situation earlier in the year with a gap down to 50p area also. In the end it filled. | ![]() brasso3 | |
18/10/2020 12:09 | AVCT :-) Cheers Wan :-) free stock charts from uk.advfn.com | wanobi | |
18/10/2020 12:00 | Hoping EVG might push on this week, but we shall see, GLA Holders, Cheers Wan :-) free stock charts from uk.advfn.com | wanobi | |
18/10/2020 11:45 | A very good summary Covid-19: The global crisis — in data | ![]() brasso3 | |
18/10/2020 10:50 | The Stigologist Thanks for the prompt reply and if I understand it correctly 4D were/are pleased to present 3 posters at the SITC and from that you have deduced, that they are excited. I see that they do mention MRx0518 as a monotherapy in their tweets 4D pharma @4dpharmaplc · Oct 14 @4dpharmaplc #DDDD to deliver 3 presentations at The Society for Immunotherapy of Cancer @sitcancer Annual Meeting 2020, including data from neoadjuvant monotherapy #clinical trial in patients awaiting surgical resection of solid #tumors [...] 4D pharma @4dpharmaplc · Oct 14 @4dpharmaplc #DDDD $DDDD will be presenting not 1, not 2, but 3 posters at @sitcancer #SITC2020 9-14 Nov! Including the first MRx0518 monotherapy immune modulation and safety data, and updates on MRx0518 + #Keytruda They did the same for MRx0518/Keytruda at last year's SITC. Presumably if there is any additional news on either therapy, we will hear about it through the normal regulatory news channels, before the conference virtual presentations.Last year the relevant rns was released on 6th November, the start date of SITC 2019. | ![]() winston66 | |
18/10/2020 10:35 | 4D they were so excited about presenting 2 posters at SITC they jumped the gun and tweeted then quickly deleted a tweet about being PLEASED to present 2 posters that seems an indication of excitement they have since confirmed it will be 3 presentations in their tweets they stress MONOTHERAPY since then we had SITC breaking their own embargo and releasing abstracts on REPL Replimune Phase I cancer data causing $600m+ spike in REPL value | ![]() the stigologist | |
18/10/2020 10:11 | Alasdair Macleod latest podcast | ![]() brasso3 | |
18/10/2020 10:06 | wanobi I do hope you don't mind me posting this here but I'm not allowed to comment on the 4D board.If you would rather it was removed I will of course oblige. The Stigologist I'm glad I've caught up with you. You posted this recently, on the 4D board. Can you give a link to the comment saying that 4D are excited and what it exactly relates to. If it's just the part A MRx0518/keytruda results then that's taken as read but does it also apply to the monotherapy trial of 0518 in solid tumours. That's quite an important distinction. We don't want to mislead people do we ? TIA The Stigologist15 Oct '20 - 21:33 - 11782 of 11911 0 8 0 4D mentioned in that story. We have 3 shots at goal at SITC Imagine they could all be v.good Open Label trials at least in 2 cases so chances v.good. You don't say you're excited if you're going to present duff data. | ![]() winston66 | |
18/10/2020 09:18 | Video explaining Crispr for AIM investors #HZD #MXCT #C4XD | ![]() the stigologist | |
18/10/2020 09:12 | Done a little twitter thread on gold investing featuring recent video clips of Jim Rogers, Thomas Kaplan and Frank Giustra | ![]() the stigologist | |
18/10/2020 08:51 | Cease fire lasted as long as the last one. Don’t see anything holding for long anytime soon looks like the Azeris are on top. ‘......Al Jazeera’s Bernard Smith, reporting from Yerevan, the Armenian capital, said it was Armenia that had pushed for the latest ceasefire. The Armenian government was under enormous pressure because of the large number of casualties, as well as the loss of territory, he explained. “The Azeris have taken, as we understand, territory that is essentially in the buffer zone between Nagorno-Karabakh and Azerbaijan. This is territory that Armenia has controlled since the 1994 ceasefire. Armenia considers it a buffer zone, a security zone, but it is Azeri territory. And for the last 26 years at least, both sides were supposed to have been negotiating the future of this territory as well as Nagorno-Karabakh,&rd “The Azeris say after 26 years, nothing has been done, there has been no solution, as to what to do with this territory, and so with Turkey’s support, they’ve been moving militarily. And they’ve succeeded in taking territory. Hence, the Armenians’ enthusiasm to push for a ceasefire.”&rs | ![]() pogue | |
18/10/2020 07:55 | Why would agree a ceasefire then break it after 4 minutes? What a mess. No sign of this clearing up quickly anymore it would seem. | ![]() qazwsxedc69 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions